← Eichor
Study identifier: NCT06971549 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Accelerated iTBS for Depression: Monitoring Brain Hemodynamics With Simultaneous iTBS/fNIRS

Condition: Depression  ·  Sponsor: The Hong Kong Polytechnic University

PhaseNA
Planned participants1
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This study will investigate the cortical hemodynamic response variability of an accelerated form of TBS stimulation over left dorsolateral prefrontal cortex (DLPFC) using a concurrent TBS/fNIRS setup. The accelerating TMS protocol that will be used in this study is similar to the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), i.e., fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) will be delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold. The investigators will recruit a depressed patient and conduct a concurrent iTBS/fNIRS protocol for each iTBS session. Moreover, the depression symptoms of the patient will be assessed before and after treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Georg Kranz, PhD  ·  27664838  ·  georg.kranz@polyu.edu.hk

Always discuss trial participation with your own doctor first.

Locations (1)

The Hong Kong Polytechnic UniversityHong Kong, Hong KongRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06971549